A Pfizer Drug Moves Closer to Approval in Another Important Indication
When investors think of Pfizer (NYSE: PFE) these days, they tend to think first of Comirnaty, the COVID-19 vaccine that it developed in collaboration with BioNTech (NASDAQ: BNTX). And since Pfizer estimates that sales of Comirnaty will hit $33.5 billion this year -- around 42% of the company's total revenue -- investors aren't incorrect to focus on that.
Source Fool.com
